Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 7Withdrawn 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Colorectal Neoplasms 1Chemoprevention 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Resveratrol × Clear all
NCT04266353 2023-05-09

Effect of Resveratrol on Serum IGF2 Among African American Women

Loma Linda University

Phase NA Withdrawn

Chemoprevention

NCT02261844 2017-03-30

Resveratrol and Human Hepatocyte Function in Cancer

University of Louisville

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡